Floatz logo

Zactima

Renal Cell Carcinoma

National Cancer Institute (NCI)Phase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

298 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Zactima is also rated in:

gliosarcomaDormant
B
Indicative ·
63 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →